Vincent Gruntz – General Manager Oncology, Novartis Pharma…
Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement…
Tagged with Novartis Oncology
Kevin Zou – Head of Oncology Asia Pacific & Country…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge…
Stefan Hendriks – Global Head Cell & Gene, Novartis…
Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in…
Novartis Oncology US: Leaning into Change
With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business…
Novartis Oncology President: “If We Offer Pay-For-Performance,…
During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement…
Novartis: CAR-T’s Journey to Market in Europe
Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene…
Emanuele Ostuni – Head of Europe, Cell & Gene Therapy,…
Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T…
